INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events... READ MORE

For US healthcare professionals

Repatha® is now available through AmgenNowTM, a direct-to-patient program. Learn more here.

Broader Coverage,
Better Access
~95% of patients are covered for Repatha® across insurance types1,*

Inclusion on formulary does not imply superior clinical efficacy or safety.

Explore Coverage Details for Repatha® Patients in Your Area

Enter your patient’s or your office’s zip code

Accessing Repatha® has Never Been Easier for Your Patients

Eighty four percentage Icon

of commercial claims are approved for Repatha®1,‡

eighty eight percentage Icon

of Medicare claims are approved for Repatha®1,‡

Seventy seven percentage Icon

of Medicaid claims are approved for Repatha®1,‡

The majority of patients with commercial insurance do not require a Prior Authorization or only have an e-step requirement2,‡

Repatha® May Cost Your Patients Less Than You Think

OVER ~80% OF REPATHA® PRESCRIPTIONS cost $50 or less across insurance types3,§

COMMERCIAL PATIENTS MAY PAY

per month with the Repatha® Co-Pay card** for eligible commercially insured patients

MEDICARE PATIENTS PAY

for ~74% of Repatha® prescriptions3,§,††

MEDICAID PATIENTS PAY

for ~99% of Repatha® prescriptions3,§

Encourage Patients to Sign up for Amgen® SupportPlus

Personalized support that you and your patients can count on across Amgen® therapies.
Learn more here

*Includes commercial, health exchange, Medicaid, and Medicare lives, as of September 2025, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha, please contact the relevant payer directly. Individual insurance requirements may vary.

†No PA requirement includes plans that implemented an electronic-step (e-step) in place of a PA. E-step is an automated, electronic health record lookback in a patient’s history to confirm certain step criteria or prescribing requirements have been met without necessitating a full prior authorization. This represents ~6% of lives.

‡Based on IQVIA claims data from 1/1/2025 to 8/29/2025. Approval rates identify the percent of all submitted new claims regardless of prior authorization requirements, if any, that have been approved during 1/1/2025 to 8/29/2025 across Commercial, Medicare, and Medicaid data. Number of attempts for approval and turnaround time may vary by patient and payer. New claims are inclusive of Repatha New to Brand patients and existing Repatha patients with new prescriptions. This information is directional and should not be interpreted as absolute values. This information is subject to change without notice; check the applicable payer policy for the most up to date information.

§Based on IQVIA claims data from 1/1/2024 to 12/20/2024 using Commercial, Medicare, and Medicaid data. Patient out-of-pocket costs and insurance requirements may vary.

**Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs.

††The patient’s out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in.

PA = prior authorization.

References: 1. Data on file, Amgen; [1]; 2025. 2. Data on file, Amgen; [2]; 2025. 3. Data on file, Amgen; [3]; 2025.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top